Matthijs A. Velders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthijs A. Velders has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Adrianus J. van Boven
3 shared publicationsBas L. van der Hoeven
2 shared publicationsHelèn Boden
2 shared publicationsJan Brouwer
2 shared publicationsMichel Queré
2 shared publicationsSjoerd H. Hofma
2 shared publications
Latest Publications
- 1 March 2015
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 10 (11) , 1280-1283
Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 March 2015
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 10 (11) , 1280-1283
Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- Open Access
- 13 February 2014
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 22 (4) , 167-173
Everolimus- and sirolimus-eluting stents in patients with and without ST-segment elevation myocardial infarction
Everolimus-eluting stents (EES) were superior to sirolimus-eluting stents (SES) in a dedicated myocardial infarction trial, a finding that was not observed in trials with low percentages of ST-elevation myocardial infarction (STEMI). Therefore, this study sought to investigate the influence of clinical presentation on outcome after EES and SES implantation.
- 13 February 2014
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 22 (4) , 167-173
Open AccessEverolimus- and sirolimus-eluting stents in patients with and without ST-segment elevation myocardial infarction
Everolimus-eluting stents (EES) were superior to sirolimus-eluting stents (SES) in a dedicated myocardial infarction trial, a finding that was not observed in trials with low percentages of ST-elevation myocardial infarction (STEMI). Therefore, this study sought to investigate the influence of clinical presentation on outcome after EES and SES implantation.
- 1 December 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 112 (12) , 1867-1872
Outcome After ST Elevation Myocardial Infarction in Patients With Cancer Treated With Primary Percutaneous Coronary Intervention
- 1 December 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 112 (12) , 1867-1872
Outcome After ST Elevation Myocardial Infarction in Patients With Cancer Treated With Primary Percutaneous Coronary Intervention
- 1 November 2013
- Published by Elsevier in Resuscitation
- Vol. 84 (11) , 1530-1535
Association between angiographic culprit lesion and out-of-hospital cardiac arrest in ST-elevation myocardial infarction patients
- 1 November 2013
- Published by Elsevier in Resuscitation
- Vol. 84 (11) , 1530-1535
Association between angiographic culprit lesion and out-of-hospital cardiac arrest in ST-elevation myocardial infarction patients
- Open Access
- 3 June 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6) , e64424
Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
Second generation drug-eluting stents were developed to improve the safety and efficacy of first generation stents. So far, limited long term randomized data exist comparing the second generation everolimus-eluting stents (EES) with first generation sirolimus-eluting stents (SES). A prospective, open-label, randomized, single center trial comparing EES and SES in all-comer patients. The primary endpoint was a composite of cardiac mortality, myocardial infarction and target vessel revascularization. Secondary endpoints included individual components of the composite, along with target lesion revascularization and stent thrombosis. In total, 977 patients were randomized, of which 498 patients to EES and 479 to SES. Average age was 65.2±11.2 years and 71.6% of the population was male. Fifty percent of patients were treated for acute coronary syndrome, more often for ST-elevation myocardial infarctions in EES patients (13.7% vs. 9.2% in SES). In contrast, SES patients more often had prior interventions and showed more calcified lesions. Two-year follow-up was available in 98% of patients. The primary endpoint occurred in 10.7% of EES patients compared to 10.6% of SES patients (HR 1.00, 95% CI 0.68–1.48). Additionally, secondary endpoints were similar between groups. The rate of stent thrombosis was low for both stent types. In this all-comer population, there were no differences in endpoints between EES and SES during two-year follow-up. Stent thrombosis rates were low, supporting the safety of drug-eluting stent appliance in clinical practice. TrialRegister.nl NTR3170
- 3 June 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6) , e64424
Open AccessTwo-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
Second generation drug-eluting stents were developed to improve the safety and efficacy of first generation stents. So far, limited long term randomized data exist comparing the second generation everolimus-eluting stents (EES) with first generation sirolimus-eluting stents (SES). A prospective, open-label, randomized, single center trial comparing EES and SES in all-comer patients. The primary endpoint was a composite of cardiac mortality, myocardial infarction and target vessel revascularization. Secondary endpoints included individual components of the composite, along with target lesion revascularization and stent thrombosis. In total, 977 patients were randomized, of which 498 patients to EES and 479 to SES. Average age was 65.2±11.2 years and 71.6% of the population was male. Fifty percent of patients were treated for acute coronary syndrome, more often for ST-elevation myocardial infarctions in EES patients (13.7% vs. 9.2% in SES). In contrast, SES patients more often had prior interventions and showed more calcified lesions. Two-year follow-up was available in 98% of patients. The primary endpoint occurred in 10.7% of EES patients compared to 10.6% of SES patients (HR 1.00, 95% CI 0.68–1.48). Additionally, secondary endpoints were similar between groups. The rate of stent thrombosis was low for both stent types. In this all-comer population, there were no differences in endpoints between EES and SES during two-year follow-up. Stent thrombosis rates were low, supporting the safety of drug-eluting stent appliance in clinical practice. TrialRegister.nl NTR3170
- 1 February 2013
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 8 (10) , 1199-1206
Long-term outcome of second-generation everolimus-eluting stents and Endeavor zotarolimus-eluting stents in a prospective registry of ST-elevation myocardial infarction patients
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 February 2013
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 8 (10) , 1199-1206
Long-term outcome of second-generation everolimus-eluting stents and Endeavor zotarolimus-eluting stents in a prospective registry of ST-elevation myocardial infarction patients
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)